Clinical Report

Transcatheter aortic valve implantation in end-stage renal disease

Patrick Hamilton1, Arthur Coverdale2,3, Colin Edwards3,6, John Ormiston2,4,5, Jim Stewart2,3, Mark Webster2 and Janak de Zoysa3,6

1Department of Medicine, North Shore Hospital, Auckland, New Zealand, 2Greenlane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand, 3Department of Medicine, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland, New Zealand, 4Department of Cardiology, North Shore Hospital, Auckland, New Zealand, 5Mercy Angiography, Mercy Hospital, Auckland, New Zealand and 6Department of Renal Medicine, North Shore Hospital, Auckland, New Zealand

Correspondence and offprint requests to: Janak de Zoysa; E-mail: janak.dezoysa@waitematadhb.govt.nz

Abstract
Valvular heart disease is common in patients with end-stage renal disease and, if symptomatic, may lead to valve replacement surgery. However, some patients with renal failure are deemed unsuitable for cardiac surgery, and in those patients who do undergo surgery, there is a significantly greater morbidity and mortality. Transcatheter aortic valve implantation (TAVI) is recognized as an option for high-risk patients with symptomatic aortic stenosis (AS). Here we describe two patients on haemodialysis who underwent TAVI with satisfactory outcomes. The role of TAVI is evolving and has the potential to play an important role for dialysis patients with AS.

Keywords: aortic stenosis; end-stage renal disease; haemodialysis; transcatheter aortic valve implantation

Background
Abnormalities of the cardiac valves are common in patients with end-stage renal disease (ESRD). Mitral and aortic calcification is seen in 10–55% of patients with ESRD [1–5]. Aortic stenosis (AS) is the most commonly seen symptomatic valve lesion [6]. Surgical valve replacement for symptomatic patients is indicated for those of acceptable risk, but there are others who are unsuitable or at high risk because of technical contraindications, multiple comorbidities or physical frailty. Transcatheter aortic valve implantation (TAVI) with a bioprosthetic valve is increasingly employed as an alternative therapy for high-risk or inoperable patients with severe AS.

Percutaneous TAVI was first described in 2002 [7]. Its subsequent commercial development and refinement have allowed transcatheter treatment of AS in selected patients. These have shown benefit compared to standard medical care [8] and similar early and medium-term outcomes compared to the surgical approach [9]. Minimal data exist regarding patients on renal replacement therapy treated by TAVI. In this report, we describe two patients with ESRD who underwent TAVI and discuss its role in this clinical setting.

Case 1

A 46-year-old man was born with complex congenital heart disease including transposition of the great arteries, situs inversus, atrial and ventricular septal defects and stenosis of the pulmonary outflow tract. He underwent several cardiac operations throughout childhood. In 1997, he underwent an orthotopic heart transplantation due to severe failure of the systemic (morphologic right) ventricle. He developed progressive renal impairment, requiring dialysis, despite withdrawal of the calcineurin inhibitor. Upper arm fistulae could not be created due to heart disease, previous thoracic operations and altered vasculature. The patient commenced peritoneal dialysis in 2006, but this was complicated by peritonitis requiring catheter removal. He was eventually established on home haemodialysis through a right femoral fistula in 2007, with an intention to proceed to a live donor renal transplant. However, he developed rapidly progressive AS: in 2005, the maximum aortic velocity on transthoracic echocardiogram (TTE) was 2.1 m/sec, increasing to 5.1 m/sec in 2008, with a mean aortic valve gradient of 66 mmHg. The situation was considered inoperable due to technical considerations. Balloon aortic valvuloplasty was performed in July 2009 but was of limited success: the mean gradient 1 day before and after the procedure fell from 69 to 53 mmHg. One month later, TAVI was performed from the left femoral artery, with left radial artery cannulation for aortography. A 29-mm CoreValve prosthesis (Medtronic, Minneapolis, MN) was inserted with a fall in mean gradient to 18 mmHg and mild paravalvular aortic regurgitation. A DDD pacemaker was inserted shortly afterwards for intermittent complete heart block and symptomatic ventricular standstill. A year later, the patient received a live donor renal transplant and remains independent of dialysis. A repeat TTE in September 2011 showed normal aortic valve function with mild aortic regurgitation.

Case 2

An 85-year-old man, with anti-neutrophil cytoplasmic antibody-positive vasculitis, developed ESRD and was...

© The Author 2012. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For permissions, please e-mail: journals.permissions@oup.com
commenced on haemodialysis, but continued to experience New York Heart Association Class IV symptoms. A TTE showed severe AS with no regurgitation (maximum aortic velocity 4.3 m/sec, a mean gradient of 42 mmHg, aortic valve area <0.8 cm²). The patient underwent pre-emptive dual chamber pacemaker implantation for bifascicular block, followed 4 days later by TAVI with a 26 mm Edwards SAPIEN prosthesis (Edwards Lifesciences, Irvine, CA). He remains dialysis dependant but has noted a significant improvement in his exercise tolerance; he is able to walk 4 km without hindrance and recently celebrated his 60th wedding anniversary. A repeat TTE, 4 months after TAVI, showed a stable bioprosthetic valve with a mean aortic gradient of 8.5 mmHg and no regurgitation.

Discussion

Moderate AS is seen in up to 9% of ESRD patients [10, 11, 12], with symptomatic AS seen in 3% of haemodialysis patients [11]. Dialysis patients have a high incidence of risk factors that are recognized to predispose to cardiovascular disease, such as hypertension, dyslipidaemia and diabetes mellitus. In addition, patients with ESRD have specific risk factors that contribute to this increased incidence. These include the uraemic milieu, inflammation, secondary hyperparathyroidism, increased calcium-phosphate product, use of calcium-based phosphate binders and abnormal vascular calcification [13]. Heart valve disease appears to occur 10–20 years earlier in ESRD patients than in the general population [6, 10, 11] and progresses more rapidly [11, 14, 15].

Surgical valve replacement is the established treatment for symptomatic AS. It is accepted that patients given a bioprosthetic or mechanical valve have a better outcome than those treated medically or by balloon valvuloplasty. In the general population, AS is predominantly a disease of the elderly, many of whom have multiple comorbidities; at least a third of all patients are deemed unsuitable for surgery [16]. It is unclear how many patients with ESRD and clinically symptomatic valvular heart disease are either not referred or are declined for cardiac surgery. In addition, patients with ESRD who undergo cardiac surgery have an increase in both morbidity and mortality [17, 18]. For patients deemed unfit for surgery, the treatment options are limited and there is a high mortality rate and significant reduction in quality of life [19].

TAVI is an emerging technology that allows implantation of a prosthetic valve without the need for a median sternotomy or cardiopulmonary bypass (Figure 1). It is currently employed in patients with symptomatic AS in whom comorbidities or technical issues make the patient inoperable or at high risk for surgical valve replacement. The early experience reported a technical success of 75% and 30-day mortality of 22% [20]. Improved patient selection, increased operator experience and newer implantable valves of lower profile with better delivery systems have all contributed to steadily improving outcomes. Recent registries report technical success in over 98% and 30-day survival in over 87% of patients [21, 22, 23]. Accepted indications and contraindications for TAVI have now evolved [24]. TAVI is associated with an improvement in aortic valve area, aortic valve gradient, quality of life, functional capacity and 6-min walk distance [25].

There are significant risks associated with TAVI. Valve frame compression of the conduction system may cause heart block, requiring a permanent pacemaker. This is particularly likely in patients with pre-existing conduction disease, and those treated with the CoreValve prosthesis, 30–40% of whom will need pacing [26]. A clinically apparent stroke is described in up to 5% of patients [8, 9]. However, more subtle neurologic impairment is likely to be more frequent with systematic magnetic resonance imaging studies demonstrating new cerebral perfusion defects in 72–91% of patients [27, 28]. Coronary obstruction causing myocardial ischaemia or infarction has been reported in up to 4% of patients [25]; that incidence is likely to fall with more rigorous assessment of aortic sinus dimensions and coronary height during pre-procedure patient evaluation. A mild paravalvular leak is common after TAVI [25]. More significant regurgitation may require further balloon dilatation or implantation of another valve. Vascular access site complications associated with the large-bore access sheath are also common, although the incidence is less with current generation 18F than earlier 24F [25].

The initial results from clinical trials have suggested that TAVI is a promising therapy when used in selected patients. Here, we describe two patients with ESRD, who underwent TAVI for symptomatic AS, an encouraging short-term outcome of TAVI in this particular high-risk population. Ongoing assessment of the valve function in our patients continues as long-term data for patients undergoing TAVI are unavailable and accelerated degeneration of surgical bioprosthetic valves has been reported in ESRD [29]. TAVI represents an important emerging therapeutic option for patients with ESRD.

Acknowledgements. The authors would like to thank Dr Janeen Milner, General Practitioner, for reviewing and commenting on the manuscript.

Conflict of interest statement. None declared.
References

1. Forman MB, Virmani R, Robertson RM et al. Mitral annular calcification in chronic renal failure. Chest 1984; 85: 367
2. Strikebaugh J, Lavin CJ, Milani RV et al. Doppler echocardiographic assessment of valvular heart disease in patients requiring hemodialysis for end-stage renal disease. South Med J 1995; 88: 65
3. Bryg RJ, Gordon PR, Migdal SD. Doppler-detected tricuspid, mitral or aortic regurgitation in end-stage renal disease. Am J Cardiol 1989; 63: 750
4. Varma R, Aronow WS, McClung JA et al. Prevalence of valve calcium and association of valve calcium with coronary artery disease, atherosclerotic vascular disease, and all-cause mortality in 137 patients undergoing hemodialysis for chronic renal failure. Am J Cardiol 2005; 95: 742
5. Straumann E, Meyer B, Misteli M et al. Aortic and mitral valve disease in patients with end stage renal disease on long-term haemodialysis. Br Heart J 1992; 67: 236
6. Baglin A, Hanslik T, Vaillant JN et al. Severe valvular heart disease in patients on chronic dialysis. A five-year multicenter French survey. Ann Med Interne (Paris) 1997; 148: 521–526
7. Cribier A. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002; 106: 3006–3008
8. Leon MB, Smith CR, Mack M et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363: 1597–1607
9. Smith CR, Leon MB, Mack MJ et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364: 2187–2198
10. Maher ER, Pazianos M, Curtis JR. Calcific aortic stenosis: a complication of chronic uraemia. Nephron 1987; 47: 119–122
11. Urena P, Malergue MC, Goldfarb B et al. Evolutionary aortic stenosis in hemodialysis patients: analysis of risk factors. Nephrology 1999; 20: 217–225
12. Castro L, Hofling B, Hassler R et al. Progression of coronary and valvular heart disease in patients on dialysis. Trans Am Soc Artif Intern Organs 1985; 31: 647–650
13. Bhon I, Thadhani R. Vascular calcification and ESRD: a hard disease, atherosclerotic vascular disease, and all-cause mortality in 137 patients undergoing hemodialysis for chronic renal failure. Am J Cardiol 2005; 95: 742
14. Perkovic V, Hunt D, Griffin SV et al. Accelerated progression of calcific aortic stenosis in dialysis patients. Nephron Clin Pract 2003; 94: c40–c45
15. Zentner D, Hunt D, Chan W et al. Prospective evaluation of aortic stenosis in end-stage kidney disease: a more fulminant process? Nephrol Dial Transplant 2010; 26: 1651–1655
16. Jung B, Baron G, Butchart EG et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003; 24: 1231–1243
17. Herzog CA. Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? Circulation 2002; 105: 1336–1341
18. Horst M, Melnhorn U, Hoesrstrup SP et al. Cardiac surgery in patients with end-stage renal disease: 10-year experience. Ann Thorac Surg 2000; 69: 96–101
19. Ben-Dor I, Pichard AD, Satlier LF et al. Clinical profile, treatment assignment and clinical outcome of patients with severe aortic stenosis not eligible to participate in a clinical trial of percutaneous aortic valve replacement. Am J Cardiol 2010; 105: 857–861
20. Cribier A, Eltchaninoff H, Tron C et al. Treatment of calcific aortic stenosis with the percutaneous heart valve. J Am Coll Cardiol 2006; 47: 1214–1223
21. Eltchaninoff H, Prot A, Girard M et al. Transcatheter aortic valve implantation: early results of the FRANCE (French Aortic National CoreValve and Edwards) registry. Eur Heart J 2011; 32: 191–197
22. Bosmans JM, Kefer J, De Bruyne B et al. Procedural, 30-day and one year outcome following CoreValve or Edwards transcatheter aortic valve implantation: results of the Belgian national registry. Interact Cardiovasc Thorac Surg 2011; 12: 762–767
23. Zahn R, Gerckens U, Grube E et al. Transcatheter aortic valve implantation: first results from a multi-centre real-world registry. Eur Heart J 2011; 32: 198–204
24. Vahanian A, Alfieri OR, Al-Attar N et al. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2008; 34: 1–8
25. Olashinska-Wisniewska A, Grygier M, Lesiak M et al. Transcatheter aortic valve implantation: the new option for high-risk patients with aortic stenosis. Cardiol J 2011; 18: 461–468
26. Khawaja MZ, Rajani R, Cook A et al. Permanent pacemaker insertion after CoreValve transcatheter aortic valve implantation: incidence and contributing factors (the UK CoreValve Collaborative). Circulation 2011; 123: 951–960
27. Ghanem A, Muller A, Nahle CP et al. Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol 2010; 55: 1427–1432
28. Astarcı P, Glineur D, Kefer J et al. Magnetic resonance imaging evaluation of cerebral embolization during percutaneous aortic valve implantation: comparison of transfemoral and transapical approaches using Edwards Sapiens valve. Eur J Cardiothorac Surg 2011; 40: 475–479
29. Chan V, Chen L, Mesana L et al. Heart valve prosthesis selection in patients with end-stage renal disease requiring dialysis: a systematic review and meta-analysis. Heart 2011; 97: 2033–2037

Received for publication: 5.3.12; Accepted in revised form: 7.3.12